Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Tesla's stock leaps on reports of Chinese approval of driving softwareUniversity of Arizona student shot to death at offSuspected alTesla, Domino's Pizza rise; AMC Entertainment, SoFi Technologies fall, Monday, 4/29/2024Russell Brand announces plan to be baptised as it's 'an opportunity to leave the past behind'A retired Roman Catholic bishop who tried to mediate between cartels in Mexico has been kidnappedTurner hits 2 home runs, Jansen also connects as Blue Jays beat Royals 6Jaguars pick up fifthAnalysis: The NHL playoffs are off to an odd start, from the net outReal Madrid coach Carlo Ancelotti apologizes for forgetting German on his Bayern Munich return
2.9021s , 6515.859375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Wonders news portal